{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:52Z","timestamp":1786119292165,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/mcg.0b013e31818ddfc6","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T08:38:17Z","timestamp":1242895097000},"page":"489-495","source":"Crossref","is-referenced-by-count":116,"title":["Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis"],"prefix":"10.1097","volume":"43","author":[{"given":"Marcus Alexander","family":"W\u00f6rns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Pfingst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Schulte-Sasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia-Martina","family":"Messow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Schulze-Bergkamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Teufel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Schuchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kanzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"D\u00fcber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Robert","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210305","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"R2-18-20210305","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"R3-18-20210305","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1634\/theoncologist.11-7-790","article-title":"Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?","volume":"11","author":"Zhu","year":"2006","journal-title":"Oncologist"},{"key":"R4-18-20210305","doi-asserted-by":"crossref","first-page":"8093","DOI":"10.1200\/JCO.2004.00.1537","article-title":"Opportunities for targeted therapies in hepatocellular carcinoma","volume":"23","author":"Thomas","year":"2005","journal-title":"J Clin Oncol"},{"key":"R5-18-20210305","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1055\/s-2005-871200","article-title":"Hepatocellular carcinoma: molecular pathways and new therapeutic targets","volume":"25","author":"Roberts","year":"2005","journal-title":"Semin Liver Dis"},{"issue":"1","key":"R6-18-20210305","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000111705","article-title":"From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now","volume":"72","author":"Pang","year":"2007","journal-title":"Oncology"},{"key":"R7-18-20210305","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"R8-18-20210305","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"R9-18-20210305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-230X-3-19","article-title":"Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis","volume":"3","author":"Huynh","year":"2003","journal-title":"BMC Gastroenterol"},{"key":"R10-18-20210305","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2006.01.008","article-title":"Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma","volume":"242","author":"Pang","year":"2006","journal-title":"Cancer Lett"},{"key":"R11-18-20210305","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jhep.2004.03.001","article-title":"Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development","volume":"41","author":"Yoshiji","year":"2004","journal-title":"J Hepatol"},{"key":"R12-18-20210305","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"R13-18-20210305","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"R14-18-20210305","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R15-18-20210305","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","article-title":"Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma","volume":"99","author":"Furuse","year":"2008","journal-title":"Cancer Sci"},{"key":"R16-18-20210305","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"R17-18-20210305","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R18-18-20210305","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"R19-18-20210305","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"R20-18-20210305","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"R22-18-20210305","first-page":"209","article-title":"Targeted therapies for hepatocellular carcinoma","volume":"6","author":"Skelton","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"R23-18-20210305","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004836-200905000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:54:56Z","timestamp":1786038896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004836-200905000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e31818ddfc6","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}